Onward Medical Initiation of coverage BUY, EUR17 Get Up, Stand Up
We are initiating Onward Medical with a BUY rating and a EUR 17 price target. Onward Medical is a clinical, soon to be commercial, Swiss-Dutch MedTech company developing two groundbreaking neuromodulating platforms for the treatment of spinal cord injury (SCI). The two platforms that the company is developing are the ARCEX, a non-invasive platform for the treatment of upper extremity restoration and the higher value ARCIM an implantable platform with initial focus on blood pressure and trunk control and mobility restoration. The company’s ARCEX platform is currently waiting for results of its pivotal Up-LIFT trial that should provide market entry in H2-23. In the implantable platform, Onward is soon to initiate first-in-human (FiH) trials for the blood pressure indication with top line data expected in Q4-22 along with an early feasibility study in mobility due to start in H1-23. We expect approval and first sales of ARCIM for blood pressure to be in H1-26 which we believe will de-risk approval for mobility 1.0 (lower leg function) which is expected to be approved also in H1-26.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.